Search Results

REGiMMUNE Limited, a biotech company focused on creating innovative immunotherapies for immune disorders and cancer, and San Fu Biotech, a subsidiary of San Fu Chemical Co., Ltd. have entered a licensing agreement to develop and commercialize RGI-2001 for the prophylaxis of acute Graft-versus-host disease in major Asian countries.

REGiMMUNE Limited announced the positive results of their Phase 2b clinical trial for the prevention of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation at the 2022 American Society of Hematology Annual Meeting.

REGiMMUNE Limited announced that the Phase 2b clinical data from 49 patients receiving RGI-2001 for the prevention of acute graft-versus-host disease will be presented at the 2022 American Society of Hematology Annual Meeting in New Orleans, Louisiana on December 12, 2022.

Previously, Dr. Duramad held a variety of positions with increasing responsibility at IGM Biosciences, Neothera Biosciences, and REGiMMUNE, leading immunology research and preclinical teams focused on oncology and autoimmune disease therapeutics.